BioSpace News Archive

HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced that company management will participate in H.C. Wainwright’s 23rd Annual Global Investment Conference, being held September 13th – 15th, 2021.

Jazz Pharmaceuticals plc announced that the company will participate in the following upcoming virtual investor conferences.

ArsenalBio, a privately held programmable cell therapy company focused on building advanced CAR T therapies for solid tumors, today announced that members of its senior management team are scheduled to participate in the Morgan Stanley 19th Annual Global Healthcare Conference on Friday, September 10, 2021 at 12:30 p.m. ET.

Translate Bio, a clinical-stage messenger RNA therapeutics company developing a new class of potentially transformative medicines to treat or prevent debilitating or life-threatening diseases, reported that on September 8, 2021, the Company granted restricted stock units for an aggregate of 54,078 shares of the Company’s common stock to twenty new employees.

Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) and the Sickle Cell Disease Association of America, Inc. (SCDAA) will host the 10th Annual Sickle Cell Disease (SCD) Therapeutics Conference on Wednesday, September 15th.

BeyondSpring Inc., a global biopharmaceutical company focused on the development of innovative cancer therapies, announced that management will present at and participate in the Morgan Stanley 19th Annual Global Healthcare Conference and R.W. Baird’s 2021 Global Healthcare Conference.

The recent U.S. Food and Drug Administration (FDA) decision to grant full approval to Pfizer’s COVID-19 vaccine is pushing public and private entities to implement widespread vaccine mandates.

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today reported the Phase Ib results of the dual Bcl-2/Bcl-xL inhibitor, APG-1252 (pelcitoclax).

The other day Shenzhen Kangtai Biological Products Co., Ltd. announced that the company and AstraZeneca signed the “Amendment 1 to License Agreement”.

Aviva Systems Biology, a market leader in antibodies, immunoassay kits, and recombinant proteins for life science research, today announced the launch of its new Protein on Demand™ semi-custom recombinant protein portfolio for life scientists conducting basic research and preclinical studies.